Kokuina E, Estévez TM, Gutiérrez Á, Ortiz A, Sánchez Y, Pérez CD

Idioma: Español
Referencias bibliográficas: 31
Paginas: 104-111
Archivo PDF: 518.86 Kb.

RESUMEN

Objetivo: el estudio está dirigido a determinar la presencia de varias especificidades antinucleares y su asociación con las afectaciones orgánicas en pacientes con lupus eritematoso sistémico.
Métodos: se obtuvieron los datos clínicos presentes en los 12 meses anteriores de 180 pacientes consecutivos con diagnóstico de lupus eritematoso sistémico. Se determinaron los anticuerpos anti-ADN de doble cadena, anti-nucleosoma, anti-Sm, anti-RNP, anti-Ro, anti-La y anti-Topo 1 por ELISA. Las asociaciones con las afectaciones orgánicas fueron evaluadas por las pruebas de chi-cuadrado y Fisher.
Resultados: los anticuerpos de mayor prevalencia en los pacientes con lupus eritematoso sistémico fueron los anti-Nuc (75.0 %). Las asociaciones más fuertes resultaron las de los anti-Nuc con la afectación neurológica (p ‹ 0.001) y articular (p ‹ 0.001); de los anti-ADNdc con citopenias (p ‹ 0.001); y de los anti-Sm y anti-RNP con la afectación neurológica (p ‹ 0.001). La asociación más significativa con la nefritis lúpica fue la del C4 sérico bajo (p ‹ 0.001). Las citopenias fue la afectación clínica asociada a la presencia de mayor variedad de anticuerpos (anti-Nuc, anti-ADNdc, anti-Sm, anti-RNP y anti-Topo 1), mientras que la afectación mucocutánea no se asoció a ningún marcador serológico.
Conclusión: los anticuerpos anti-Nuc, anti-ADNdc, anti-Sm y anti-RNP mostraron fuertes asociaciones con distintas afectaciones clínicas del lupus eritematoso sistémico. Estos datos proporcionan información clínica de utilidad para el seguimiento de los pacientes cubanos con lupus eritematoso sistémico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmun Rev. 2012;11:593-5.

2. Tan EM, Cohen AS, Fries JF, Masi AT, Mc Shane DJ, Rithfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.

3. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-86.

4. Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:1129-37.

5. Meroni PL, Biggioggero M, Pierangeli SS, Sheldon J, Zegers I, Borghi MO. Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. Nat Rev Rheumatol. 2014;10:35-43.

6. Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L, et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases. Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum. 2000;43:76-84.

7. Cervera R, Viñas O, Ramos-Casals M, Font J, Garcia-Carrasco M, Siso A, et al. Antichromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann RheumDis. 2003;62:431-4.

8. Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-Guerrero J. Antinucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology. 2004;43:220-4.

9. Braun A, Sis J, Max R, Mueller K, Fiehn C, Zeier M, et al. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol. 2007;36:291-8.

10. Su Y, Jia RL, Han L, Li ZG. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol. 2007;122:115-20.

11. Tikly M, Gould T, Wadee AA, van der Westhuizen E, Mokgethwa BB. Clinical and serological correlates of antinucleosome antibodies in South Africans with systemic lupus erythematosus. Clin Rheumatol. 2007;26:2121-5.

12. Pradhan VD, Patwardhan MM, Ghosh K. Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies. Indian J Dermatol Venereol Leprol. 2010;76:145-9.

13. Abdel Gawad ER, Mansour AI, AbdelAziz YA, Soliman AF, Fawzy RM. Role of anti-nucleosome antibodies in the diagnosis of systemic lupus erythematosus and as a marker for lupus nephropathy. Egypt J Immunol. 2014;21:57-65.

14. Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev. 2012;12:97-106.

15. Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther. 2011;13:R38.

16. Pisetsky DS. Antinuclear antibodies in rheumatic disease: a proposal for a function-based classification. Scand J Immunol. 2012;76:223-8.

17. Kiss E, Lakos G, Szegedi G, Poor G, Szodoray P. Anti-nucleosome antibody, a reliable indicator for lupus nephritis. Autoimmunity. 2009;42:393-8.

18. Shabana AA, El-Ghawet AE, Machaly SA, Abu Hashim EM, El-Kady BA, Shaat R. Anti-chromatin and anti-histone antibodies in Egyptian patients with systemic lupus erythematosus. Clin Rheumatol. 2009;28:673-8.

19. Andrejevic S, Jeremy I, Sefik-Bukilica M, Nikolic M, Stojimirovic B, Bonaci-Nikolic B. Immunoserological parameters in SLE: high-avidity anti-ds DNA detected by ELISA are the most closely associated with the disease activity Clin Rheumatol. 2013,32:1619-26.

20. O’Flynn J, Flierman R, van der Pol P, Rops A, Satchell SC, Mathieson PW et al. Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation. Mol Immunol. 2011;49:75-83.

21. Kim H-A, Jeon J-Y, Choi G-S, Sung J-M, Kim M-J, Yun J-M, et al. The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans. Clin Immunol. 2008;128:277-83.

22. Lu R, Robertson JM, Bruner BF, Guthridge JM, Neas BR, Nath SK, et al. Multiple Autoantibodies display association with lymphopenia, proteinuria, and cellular casts in a large, ethnically diverse SLE patient cohort. Autoimmune Diseases; 2012: Article ID 819634, 11 pages, doi:10.1155/2012/819634

23. Vilá LM, Molina MJ, Mayor AM, Peredo RA, Santaella ML, Vilá S. Clinical and prognostic value of autoantibodies in Puerto Ricans with systemic lupus erythematosus. Lupus. 2006;15:892-8.

24. De Giorgio LA, Konstantinov KN, Lee SC, Hardin JA, Voipe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med. 200;11:1189-93.

25. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology. 2004;43:1555-60.

26. Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I, et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis. 2003;62:556-60.

27. Villalta D, Romelli PB, Savina C, Bizzaro N, Tozzoli R, Tonutti E, et al. Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring. Lupus. 2003;12:31-6.

28. Hoffman IEA, Peene I, Meheus L, Huizinga TWJ, Cebecauer L, Isenberg D et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann RheumDis. 2004;63:1155-8.

29. Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ. Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality? Autoimmunity Reviews. 2010;9:756-60.

30. Gussin HA, Ignat GP, Varga J, Teodorescu M. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44:376-83.

31. Vilá LM, Mayor AM, Valentín AH, Rodríguez SI, Reyes ML, Acosta E, et al. Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. P R HealthSci J. 1999;18:89-94.